Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
holding | TENX | Common Stock | 266 | May 17, 2024 | Direct | F1 | |||||
holding | TENX | Common Stock | 1.19K | May 17, 2024 | By Stuart Rich 2022 Irrevocable Trust | F2, F3 | |||||
holding | TENX | Common Stock | 1.19K | May 17, 2024 | By Andrea Rich 2021 Irrevocable Trus | F2, F4 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | TENX | Stock Option (right to buy) | Award | $0 | +119 | $0.00 | 119 | May 17, 2024 | Common Stock | 119 | $3.55 | Direct | F5 | |
holding | TENX | Stock Option (right to buy) | 157 | May 17, 2024 | Common Stock | 157 | $2,848.00 | Direct | F6, F7 | |||||
holding | TENX | Stock Option (right to buy) | 63 | May 17, 2024 | Common Stock | 63 | $992.00 | Direct | F8, F9 |
Id | Content |
---|---|
F1 | These shares were previously reported as 424,347 but were adjusted to reflect the stock splits that occurred on January 4, 2023 and January 2, 2024. |
F2 | These shares were previously reported as 1,909,585, but were adjusted to reflect the stock splits that occurred on January 4, 2023 and January 2, 2024. |
F3 | The Reporting Person is special asset advisor to the Stuart Rich 2022 Irrevocable Trust, a Spousal Lifetime Access Trust (the "Trust"). As such, the Reporting Person has voting and dispositive power over the reported securities held in the Trust, however disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. |
F4 | The Reporting Person is co-trustee of the Andrea Rich 2021 Irrevocable Trust and disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. |
F5 | The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on each of May 17, 2025, May 17, 2026, May 17, 2027 and May 17, 2028, subject to the Reporting Person's continued employment. |
F6 | These options were previously reported as covering 250,000 shares at an exercise price of $1.78 per share, but were adjusted to reflect the stock splits that occurred on January 4, 2023 and January 2, 2024. |
F7 | The options vest and become exercisable in four equal installments, with 25% vesting after the start of a Phase 3 clinical trial, 25% vesting after the database lock with respect to the trial, 25% vesting after the opening of an Investigational New Drug Application with the U.S. Food and Drug Administration ("FDA"), and 25% vesting after the approval from the FDA, subject to the Reporting Person's continued employment. |
F8 | These options were previously reported as covering 100,000 shares at an exercise price of $0.62 per share, but were adjusted to reflect the stock splits that occurred on January 4, 2023 and January 2, 2024. |
F9 | The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on each of June 9, 2023, June 9, 2024, June 9, 2025, and June 9, 2026, subject to the Reporting Person's continued employment. |